US2956062A
(en)
|
1959-02-26 |
1960-10-11 |
Robins Co Inc A H |
Esters of amino alcohols
|
US6204261B1
(en)
|
1995-12-20 |
2001-03-20 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β Converting enzyme inhibitors
|
GB1219606A
(en)
|
1968-07-15 |
1971-01-20 |
Rech S Et D Applic Scient Soge |
Quinuclidinol derivatives and preparation thereof
|
IT1016489B
(it)
|
1974-03-18 |
1977-05-30 |
Isf Spa |
Inalatore
|
JPS6235216A
(ja)
|
1985-08-09 |
1987-02-16 |
Noritoshi Nakabachi |
不均質物質層の層厚非破壊測定方法および装置
|
GB8916480D0
(en)
|
1989-07-19 |
1989-09-06 |
Glaxo Group Ltd |
Chemical process
|
GB8923590D0
(en)
|
1989-10-19 |
1989-12-06 |
Pfizer Ltd |
Antimuscarinic bronchodilators
|
US5416013A
(en)
|
1990-04-04 |
1995-05-16 |
Sterling Winthrop Inc. |
Interleukin 1β protease and interleukin 1β protease inhibitors
|
PT100441A
(pt)
|
1991-05-02 |
1993-09-30 |
Smithkline Beecham Corp |
Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
|
US5451700A
(en)
|
1991-06-11 |
1995-09-19 |
Ciba-Geigy Corporation |
Amidino compounds, their manufacture and methods of treatment
|
CA2071674C
(fr)
|
1991-06-21 |
2003-08-19 |
Kevin T. Chapman |
Derives peptidiques utilises comme inhibiteurs de l'enzyme de conversion de l'interleukin-1.beta.
|
HU220098B
(hu)
|
1991-08-30 |
2001-10-28 |
Vertex Pharmaceuticals Incorporated |
Interleukin-1 béta proteáz enzim, és interleukin-1 béta proteáz inhibitorok
|
EP0547699A1
(fr)
|
1991-12-19 |
1993-06-23 |
Merck & Co. Inc. |
Dérivés peptidiques comme inhibiteurs d'enzyme convertissant l'interleukine 1-bêta
|
AU3479593A
(en)
|
1992-01-31 |
1993-09-01 |
Merck & Co., Inc. |
Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme
|
EP0627926B1
(fr)
|
1992-02-21 |
1998-08-05 |
Merck & Co., Inc. (a New Jersey corp.) |
DERIVES DE PEPTIDYLE UTILES COMME INHIBITEURS DE L'ENZYME CONVERTISSANT L'INTERLEUKINE-1$g(b)
|
WO1993018007A1
(fr)
|
1992-03-13 |
1993-09-16 |
Tokyo Tanabe Company Limited |
Nouveau derive de carbostyrile
|
US5552438A
(en)
|
1992-04-02 |
1996-09-03 |
Smithkline Beecham Corporation |
Compounds useful for treating allergic and inflammatory diseases
|
JP3251587B2
(ja)
|
1992-04-02 |
2002-01-28 |
スミスクライン・ビーチャム・コーポレイション |
炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
|
WO1993019750A1
(fr)
|
1992-04-02 |
1993-10-14 |
Smithkline Beecham Corporation |
Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
|
AU4634993A
(en)
|
1992-06-24 |
1994-01-24 |
Merck & Co., Inc. |
Dna encoding precursor interleukin 1beta converting enzyme
|
CA2139854A1
(fr)
|
1992-07-31 |
1994-02-17 |
Ralph P. Robinson |
Derives de l'acide peptidyl-4-amino-2,2-difluoro-3-oxo-1,6-hexanedioique utilises comme agents anti-inflammatoires
|
US5395958A
(en)
|
1992-09-30 |
1995-03-07 |
Mitsubishi Kasei Corporation |
Cyclopropene derivatives
|
CA2109646C
(fr)
|
1992-11-24 |
2000-03-07 |
Gaston O. Daumy |
Peptides para-nitroanilides
|
GB9301000D0
(en)
|
1993-01-20 |
1993-03-10 |
Glaxo Group Ltd |
Chemical compounds
|
US5656600A
(en)
|
1993-03-25 |
1997-08-12 |
Corvas International, Inc. |
α-ketoamide derivatives as inhibitors of thrombosis
|
US5411985A
(en)
|
1993-05-17 |
1995-05-02 |
Merck & Co., Inc. |
Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme
|
JPH0789951A
(ja)
|
1993-06-03 |
1995-04-04 |
Sterling Winthrop Inc |
インターロイキン−1β転換酵素阻害剤
|
DK0644197T3
(da)
|
1993-06-04 |
1999-06-07 |
Vertex Pharma |
Peptidphosphinyloxymethylketoner som inhibitorer af interleukin-1beta-konverterende enzymer
|
ATE163412T1
(de)
|
1993-06-08 |
1998-03-15 |
Sanofi Sa |
Pyridazine als interleukin-1-beta verwandlungsenzym inhibitoren
|
DE4326959C2
(de)
|
1993-08-12 |
1995-07-06 |
Henkel Kgaa |
Verwendung von Fettsäure-N-alkylpolyhydroxyalkylamiden
|
US6596260B1
(en)
|
1993-08-27 |
2003-07-22 |
Novartis Corporation |
Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
|
US5756466A
(en)
|
1994-06-17 |
1998-05-26 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
US5716929A
(en)
|
1994-06-17 |
1998-02-10 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1β converting enzyme
|
GB9414193D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
GB9414208D0
(en)
|
1994-07-14 |
1994-08-31 |
Glaxo Group Ltd |
Compounds
|
US5565430A
(en)
|
1994-08-02 |
1996-10-15 |
Sterling Winthrop Inc. |
Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
|
EP0865302B1
(fr)
|
1995-12-07 |
2000-05-31 |
Jago Pharma Ag |
Inhalateur fournissant des doses multiples d'une poudre seche pharmacologique
|
US5843904A
(en)
|
1995-12-20 |
1998-12-01 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of interleukin-1βconverting enzyme
|
DE69711845T2
(de)
|
1996-09-12 |
2002-10-31 |
Idun Pharmaceuticals Inc |
Neue tricyclische verbindungen mit ice/ced-3 protease familie-hemmenden eigenschaften
|
DE69734718T2
(de)
|
1996-09-12 |
2006-08-24 |
Idun Pharmaceuticals, Inc., San Diego |
Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
|
JP3492703B2
(ja)
|
1996-09-12 |
2004-02-03 |
アイドゥン ファーマシューティカルズ,インコーポレイテッド |
システインプロテアーゼのICE/ced―3ファミリーの阻害剤としてのC―末端変性(N―置換)―2―インドリルジペプチド
|
US6610683B2
(en)
|
1996-09-12 |
2003-08-26 |
Idun Pharmaceuticals, Inc. |
Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
|
GB9622386D0
(en)
|
1996-10-28 |
1997-01-08 |
Sandoz Ltd |
Organic compounds
|
US6613795B2
(en)
|
1996-11-11 |
2003-09-02 |
Christian Noe |
Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
|
SI0937041T1
(en)
|
1996-11-11 |
2003-10-31 |
Christian R. Noe |
Use of a pharmaceutically acceptable salt of (3R,2'R)-3-((Cyclopently-hydroxyphenylacetyl)oxy)-1,1-dimethyl-pyrrolidinium for the preparation of a medicament
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
US6054487A
(en)
|
1997-03-18 |
2000-04-25 |
Basf Aktiengesellschaft |
Methods and compositions for modulating responsiveness to corticosteroids
|
EP0998300A1
(fr)
|
1997-03-18 |
2000-05-10 |
Basf Aktiengesellschaft |
Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
|
AR016384A1
(es)
|
1997-07-30 |
2001-07-04 |
Smithkline Beecham Corp |
Inhibidores de caspasas, composiciones farmaceuticas que comprenden dichos inhibidores de caspasas y uso de los inhibidores de caspasas para prepararun medicamento util para el tratamiento de apoptosis y desordenes asociados con excesiva actividad de la convertosa il-1 beta.
|
AU9281298A
(en)
|
1997-10-01 |
1999-04-23 |
Kyowa Hakko Kogyo Co. Ltd. |
Benzodioxole derivatives
|
GB9723589D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723590D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
GB9723566D0
(en)
|
1997-11-08 |
1998-01-07 |
Glaxo Group Ltd |
Chemical compounds
|
YU44900A
(sh)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
|
PE20000270A1
(es)
|
1998-02-14 |
2000-05-20 |
Glaxo Group Ltd |
Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
|
DE69939689D1
(de)
|
1998-03-19 |
2008-11-20 |
Vertex Pharma |
Caspase inhibitoren
|
US6362371B1
(en)
|
1998-06-08 |
2002-03-26 |
Advanced Medicine, Inc. |
β2- adrenergic receptor agonists
|
AR019322A1
(es)
|
1998-06-18 |
2002-02-13 |
Smithkline Beecham Corp |
Derivados de sulfonilo sustituido por heterociclo-etanodionanilina sustituida por heterociclo, composicion farmaceutica que los contiene y su uso para lamanufactura de un medicamento
|
US6495528B1
(en)
|
1998-06-23 |
2002-12-17 |
Smithkline Beecham Corporation |
2-(Purin -9-yl)-tetrahydrofuran-3,4-diol derivatives
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
GB9813565D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
GB9813540D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
JP4369053B2
(ja)
|
1998-06-30 |
2009-11-18 |
ダウ グローバル テクノロジーズ インコーポレイティド |
ポリマーポリオール及びその製造方法
|
ES2234266T3
(es)
|
1998-07-24 |
2005-06-16 |
Jago Research Ag |
Formulaciones medicas para aerosoles.
|
CA2347512C
(fr)
|
1998-10-16 |
2005-12-06 |
Pfizer Inc. |
Derives d'adenine
|
EP1862164A3
(fr)
|
1998-11-13 |
2012-12-26 |
Jagotec AG |
Poudre sèche pour inhalation
|
GB9902689D0
(en)
|
1999-02-08 |
1999-03-31 |
Novartis Ag |
Organic compounds
|
DE19921693A1
(de)
|
1999-05-12 |
2000-11-16 |
Boehringer Ingelheim Pharma |
Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
|
GB9913083D0
(en)
|
1999-06-04 |
1999-08-04 |
Novartis Ag |
Organic compounds
|
YU25500A
(sh)
|
1999-05-11 |
2003-08-29 |
Pfizer Products Inc. |
Postupak za sintezu analoga nukleozida
|
US20040002548A1
(en)
*
|
1999-05-12 |
2004-01-01 |
Boehringer Ingelheim Pharma Kg |
Medicament compositions containing anticholinergically-effective compounds and betamimetics
|
US6683115B2
(en)
|
1999-06-02 |
2004-01-27 |
Theravance, Inc. |
β2-adrenergic receptor agonists
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
US6322771B1
(en)
|
1999-06-18 |
2001-11-27 |
University Of Virginia Patent Foundation |
Induction of pharmacological stress with adenosine receptor agonists
|
JP5038568B2
(ja)
|
1999-08-21 |
2012-10-03 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
協力剤の組合せ物
|
WO2001019373A2
(fr)
|
1999-09-17 |
2001-03-22 |
Basf Aktiengesellschaft |
Procedes et compositions permettant de moduler la sensibilite aux corticosteroides
|
CO5180581A1
(es)
|
1999-09-30 |
2002-07-30 |
Pfizer Prod Inc |
Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
OA11558A
(en)
|
1999-12-08 |
2004-06-03 |
Advanced Medicine Inc |
Beta 2-adrenergic receptor agonists.
|
GB0003960D0
(en)
|
2000-02-18 |
2000-04-12 |
Pfizer Ltd |
Purine derivatives
|
US6369115B1
(en)
|
2000-03-20 |
2002-04-09 |
Dura Pharmaceuticals, Inc. |
Stabilized powder formulations
|
GB0008660D0
(en)
|
2000-04-07 |
2000-05-31 |
Arakis Ltd |
The treatment of respiratory diseases
|
BR0110331A
(pt)
|
2000-04-27 |
2003-01-07 |
Boehringer Ingelheim Pharma |
Substâncias que mimetizam beta que têm uma atividade de longa duração, processos para prepará-las e o uso das mesmas como medicamentos
|
TWI227240B
(en)
|
2000-06-06 |
2005-02-01 |
Pfizer |
2-aminocarbonyl-9H-purine derivatives
|
KR100751981B1
(ko)
|
2000-06-27 |
2007-08-28 |
라보라토리오스 살바트, 에스.에이. |
아릴알킬아민으로부터 유도된 카바메이트
|
GB0015727D0
(en)
|
2000-06-27 |
2000-08-16 |
Pfizer Ltd |
Purine derivatives
|
GB0015876D0
(en)
|
2000-06-28 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
DE10038639A1
(de)
|
2000-07-28 |
2002-02-21 |
Schering Ag |
Nichtsteroidale Entzündungshemmer
|
EP1305329B2
(fr)
|
2000-08-05 |
2015-03-18 |
Glaxo Group Limited |
6.alpha., 9.alpha.-difluoro-17.alpha.-(2-furanylcarboxyle) oxy-11.beta.-hydroxy-16.alpha.-methyle-3-oxo-androst-1,4-diene-17-acide carbothioique s-fluoromethyle ester utilise comme agent anti inflammatoire
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
US20020193392A1
(en)
|
2000-11-13 |
2002-12-19 |
Christel Schmelzer |
Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
|
GB0028383D0
(en)
|
2000-11-21 |
2001-01-03 |
Novartis Ag |
Organic compounds
|
GB0029562D0
(en)
|
2000-12-04 |
2001-01-17 |
Novartis Ag |
Organic compounds
|
CA2441896A1
(fr)
|
2000-12-22 |
2002-07-04 |
Almirall Prodesfarma Ag |
Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
|
CN1250545C
(zh)
|
2000-12-28 |
2006-04-12 |
阿尔米雷尔普罗迪斯制药有限公司 |
新的奎宁环衍生物类及含有这类衍生物的药物组合物
|
US20020179087A1
(en)
|
2001-02-01 |
2002-12-05 |
Karl-Heinz Bozung |
Pharmaceutical compositions containing an oxitropium salt and a betamimetic
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
ATE365720T1
(de)
|
2001-03-08 |
2007-07-15 |
Glaxo Group Ltd |
Agonisten von beta-adrenorezeptoren
|
EP1241176A1
(fr)
|
2001-03-16 |
2002-09-18 |
Pfizer Products Inc. |
Dérivés de purine pour le traitement de l'ischémie
|
ATE381537T1
(de)
|
2001-03-22 |
2008-01-15 |
Glaxo Group Ltd |
Formanilid-derivative als beta2-adrenorezeptor- agonisten
|
EP1381602A1
(fr)
|
2001-04-19 |
2004-01-21 |
Vertex Pharmaceuticals Incorporated |
Heterocyclyl-dicarbamides en tant qu'inhibiteurs de caspase
|
BR0209271A
(pt)
|
2001-04-30 |
2004-06-15 |
Glaxo Group Ltd |
Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
|
US20040171576A1
(en)
|
2001-05-25 |
2004-09-02 |
Michael Yeadon |
Adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
|
US20040248867A1
(en)
|
2001-06-12 |
2004-12-09 |
Keith Biggadike |
Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
|
EP1578910A4
(fr)
|
2001-06-21 |
2008-06-04 |
Verenium Corp |
Nitrilases
|
ITMI20010357U1
(it)
|
2001-06-28 |
2002-12-30 |
Plastiape Spa |
Dispositivo inalatore
|
SI1425001T1
(sl)
|
2001-09-14 |
2009-04-30 |
Glaxo Group Ltd Glaxo Welcome |
Fenetanolaminski derivati za zdravljenje respiratornih bolezni
|
CZ2004501A3
(cs)
|
2001-10-17 |
2004-09-15 |
Ucb, S.A. |
Chinuklidinové deriváty, způsoby jejich přípravy a jejich použití jako M2 a/nebo M3 inhibitoru muskarinového receptoru
|
GB0125259D0
(en)
|
2001-10-20 |
2001-12-12 |
Glaxo Group Ltd |
Novel compounds
|
AR037517A1
(es)
|
2001-11-05 |
2004-11-17 |
Novartis Ag |
Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
|
AU2002359365B2
(en)
|
2001-11-09 |
2008-07-10 |
Gilead Sciences, Inc. |
A2B adenosine receptor antagonists
|
US6653323B2
(en)
|
2001-11-13 |
2003-11-25 |
Theravance, Inc. |
Aryl aniline β2 adrenergic receptor agonists
|
TWI249515B
(en)
|
2001-11-13 |
2006-02-21 |
Theravance Inc |
Aryl aniline beta2 adrenergic receptor agonists
|
AU2002356759A1
(en)
|
2001-12-01 |
2003-06-17 |
Glaxo Group Limited |
17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
|
IL162596A0
(en)
|
2001-12-20 |
2005-11-20 |
S A L V A T Lab Sa |
1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
|
AU2003202044A1
(en)
|
2002-01-15 |
2003-09-09 |
Glaxo Group Limited |
17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
|
AU2003201693A1
(en)
|
2002-01-21 |
2003-09-02 |
Glaxo Group Limited |
Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
|
GB0202216D0
(en)
|
2002-01-31 |
2002-03-20 |
Glaxo Group Ltd |
Novel compounds
|
GB0204719D0
(en)
|
2002-02-28 |
2002-04-17 |
Glaxo Group Ltd |
Medicinal compounds
|
US6933410B2
(en)
|
2002-03-08 |
2005-08-23 |
Novartis Ag |
Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
|
ES2298508T3
(es)
|
2002-03-26 |
2008-05-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos.
|
CA2477764A1
(fr)
|
2002-03-26 |
2003-10-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
|
WO2003086408A1
(fr)
|
2002-04-10 |
2003-10-23 |
University Of Virginia Patent Foundation |
Utilisation d'agonistes du recepteur d'adenosine a2a dans le traitement de maladies inflammatoires
|
DE60335869D1
(de)
|
2002-04-11 |
2011-03-10 |
Merck Sharp & Dohme |
1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
|
ES2206021B1
(es)
|
2002-04-16 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de pirrolidinio.
|
EP1497261B1
(fr)
|
2002-04-25 |
2007-12-19 |
Glaxo Group Limited |
Derives de la phenethanolamine
|
US6747043B2
(en)
|
2002-05-28 |
2004-06-08 |
Theravance, Inc. |
Alkoxy aryl β2 adrenergic receptor agonists
|
ES2201907B1
(es)
|
2002-05-29 |
2005-06-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
|
US7186864B2
(en)
|
2002-05-29 |
2007-03-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
DE10224888A1
(de)
|
2002-06-05 |
2003-12-24 |
Merck Patent Gmbh |
Pyridazinderivate
|
US7074806B2
(en)
|
2002-06-06 |
2006-07-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
DE10225574A1
(de)
|
2002-06-10 |
2003-12-18 |
Merck Patent Gmbh |
Aryloxime
|
DE10227269A1
(de)
|
2002-06-19 |
2004-01-08 |
Merck Patent Gmbh |
Thiazolderivate
|
EP1517895B1
(fr)
|
2002-06-25 |
2007-03-14 |
Merck Frosst Canada Ltd. |
Inhibiteurs de pde4 8-(biaryle)quinolines
|
ES2204295B1
(es)
|
2002-07-02 |
2005-08-01 |
Almirall Prodesfarma, S.A. |
Nuevos derivados de quinuclidina-amida.
|
EP1519922A1
(fr)
|
2002-07-02 |
2005-04-06 |
Merck Frosst Canada & Co. |
Ethane pyridone a substitution diaryle, inhibiteurs d'enzyme pde4
|
PT1521733E
(pt)
|
2002-07-08 |
2014-10-29 |
Pfizer Prod Inc |
Moduladores do recetor de glucocorticoides
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
TW200409746A
(en)
|
2002-07-26 |
2004-06-16 |
Theravance Inc |
Crystalline β2 adrenergic receptor agonist
|
AR040962A1
(es)
*
|
2002-08-09 |
2005-04-27 |
Novartis Ag |
Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
|
JP4555684B2
(ja)
|
2002-08-10 |
2010-10-06 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Pde4阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン
|
CA2494643A1
(fr)
|
2002-08-10 |
2004-03-04 |
Altana Pharma Ag |
Derives de n-oxyde de piperidine
|
CA2494650A1
(fr)
|
2002-08-10 |
2004-03-04 |
Altana Pharma Ag |
Derives de pyridazinone utilises comme inhibiteurs de pde4
|
AU2003255376A1
(en)
|
2002-08-10 |
2004-03-11 |
Altana Pharma Ag |
Piperidine-derivatives as pde4 inhibitors
|
WO2004018465A2
(fr)
|
2002-08-17 |
2004-03-04 |
Altana Pharma Ag |
Nouvelles benzonaphtyridines
|
CA2495597A1
(fr)
|
2002-08-17 |
2004-03-04 |
Altana Pharma Ag |
Nouvelles phenanthridines
|
GB0219512D0
(en)
|
2002-08-21 |
2002-10-02 |
Norton Healthcare Ltd |
Inhalation compositions with high drug ratios
|
CA2496175A1
(fr)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
|
EP1534675B1
(fr)
|
2002-08-23 |
2009-02-25 |
Ranbaxy Laboratories, Ltd. |
Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
|
WO2004019944A1
(fr)
|
2002-08-29 |
2004-03-11 |
Altana Pharma Ag |
2-hydroxy-6-phenylphenanthridines utilisees comme inhibiteurs de pde-4
|
WO2004019945A1
(fr)
|
2002-08-29 |
2004-03-11 |
Altana Pharma Ag |
3-hydroxy-6-phenylphenanthridines en tant qu'inhibiteurs de pde-4
|
BR0313923A
(pt)
|
2002-08-29 |
2005-07-12 |
Boehringer Ingelheim Pharma |
Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
|
GB0220730D0
(en)
|
2002-09-06 |
2002-10-16 |
Glaxo Group Ltd |
Medicinal compounds
|
JP2006096662A
(ja)
|
2002-09-18 |
2006-04-13 |
Sumitomo Pharmaceut Co Ltd |
新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤
|
AU2003270783C1
(en)
|
2002-09-20 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
|
JP2004107299A
(ja)
|
2002-09-20 |
2004-04-08 |
Japan Energy Corp |
新規1−置換ウラシル誘導体及びアレルギー性疾患の治療剤
|
DE10246374A1
(de)
|
2002-10-04 |
2004-04-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
JP4490911B2
(ja)
|
2002-10-11 |
2010-06-30 |
ファイザー・インク |
β−2アゴニストとしてのインドール誘導体
|
AU2003298094A1
(en)
|
2002-10-22 |
2004-05-13 |
Glaxo Group Limited |
Medicinal arylethanolamine compounds
|
BR0314721A
(pt)
|
2002-10-23 |
2005-08-02 |
Glenmark Pharmaceuticals Ltd |
Compostos tricìclicos úteis para tratamento de distúrbios inflamatórios e alérgicos, processo para sua preparação e composições farmacêuticas contendo-os
|
ATE390407T1
(de)
|
2002-10-28 |
2008-04-15 |
Glaxo Group Ltd |
Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
|
GB0225287D0
(en)
|
2002-10-30 |
2002-12-11 |
Glaxo Group Ltd |
Novel compounds
|
GB0225540D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0225535D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
DE10253220A1
(de)
|
2002-11-15 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
DE10253282A1
(de)
|
2002-11-15 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
|
DE10253426B4
(de)
|
2002-11-15 |
2005-09-22 |
Elbion Ag |
Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
|
DE10261874A1
(de)
|
2002-12-20 |
2004-07-08 |
Schering Ag |
Nichtsteroidale Entzündungshemmer
|
NZ541232A
(en)
|
2003-01-09 |
2008-02-29 |
Astellas Pharma Inc |
Pyrrolopyridazine derivatives
|
US7732432B2
(en)
|
2003-01-21 |
2010-06-08 |
Merck Sharp & Dohme Corp. |
17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
|
TWI324150B
(en)
|
2003-02-28 |
2010-05-01 |
Novartis Ag |
Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
|
EP1460064A1
(fr)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Derivés de Indole-2-carboxamide comme beta-2 agonistes
|
PE20100399A1
(es)
|
2003-04-02 |
2010-06-01 |
Novartis Ag |
Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
|
PT1613315E
(pt)
|
2003-04-04 |
2009-04-22 |
Novartis Ag |
Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
GB0312832D0
(en)
|
2003-06-04 |
2003-07-09 |
Pfizer Ltd |
2-amino-pyridine derivatives useful for the treatment of diseases
|
CA2527334A1
(fr)
|
2003-06-04 |
2004-12-16 |
Pfizer Inc. |
Derives de 2-amino-pyridine utiles comme agonistes de recepteurs beta-2 adrenergiques
|
US7439260B2
(en)
|
2003-06-11 |
2008-10-21 |
Merck Forsst Canada & Co. |
7-(1,3-thiazol-2-YL)thio-coumarin derivatives and their use as leukotriene biosynthesis inhibitors
|
TW200510298A
(en)
|
2003-06-13 |
2005-03-16 |
Theravance Inc |
Substituted pyrrolidine and related compounds
|
WO2004111044A1
(fr)
|
2003-06-17 |
2004-12-23 |
Glenmark Pharmaceuticals Ltd. |
Composes tricycliques efficaces dans le traitement des affections inflammatoires et allergiques : leur procede de preparation
|
SE527189C2
(sv)
*
|
2003-06-19 |
2006-01-17 |
Microdrug Ag |
Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
WO2005082413A2
(fr)
*
|
2004-02-27 |
2005-09-09 |
Altana Pharma Ag |
Combinaison de ciclesonide et de glycopyrronium
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
US20060239935A1
(en)
*
|
2005-04-23 |
2006-10-26 |
Boehringer Ingelheim International Gmbh |
Compositions for inhalation
|
EP2778064A1
(fr)
|
2013-03-14 |
2014-09-17 |
Airbus Operations GmbH |
Fourniture de services pour passagers d'un moyen de transport
|
EP3197429A1
(fr)
|
2014-09-25 |
2017-08-02 |
Boehringer Ingelheim Vetmedica GmbH |
Polythérapie avec des inhibiteurs de sglt2 et des agonistes de la dopamine utilisée pour la prévention des troubles métaboliques chez des équidés
|